Reset

Advanced Filters
Friday

Heart Failure is a chronic disease that can progress to an advanced state. Several studies have shown that referral to a comprehensive heart failure disease management center can improve outcomes. Recognition of the signs and symptoms of advanced heart failure allows for timely referral for advanced heart failure therapies including heart transplant and ventricular assist devices. Using risk models and identifying sentinel clinical features can help clinicians refer patients early allowing for improved outcomes. Comprehensive heart failure disease management programs also can facilitate palliative care interventions for those who are not candidates for or who do not wish advanced therapies.

Objectives:
  • Participants will know the signs and symptoms of advanced heart failure.
  • Participants will understand the indications and contraindications for heart transplant and mechanical circulatory support.
  • Participants will understand the role of risk models and key clinical events to trigger referral to comprehensive heart failure programs.
Friday
08:45am - 09:30am EDT - November 6, 2020
Paul Forfia, MD
Credits Available:
0.75 CE

Objectives:
  • The audience will be able to tell the difference between Pre-Capillary and Post-Capillary Pulmonary Hypertension by using PA Catheter measurements.
  • They will be able to understand the importance of making that diagnosis prior to ordering any therapy.
  • Include case studies for the audience to use the skill they were taught to for a diagnosis and plan.
Friday
09:30am - 10:15am EDT - November 6, 2020
Meredith Brisco-Bacik, MD, MSCE
Credits Available:
0.75 CE

Renal dysfunction in heart failure portends adverse outcomes and often limits aggressive medical and decongestive therapies. Despite the high prevalence in this population, not all forms of renal dysfunction are prognostically or mechanistically equivalent: renal dysfunction can result from irreversible nephron loss secondary to diabetes or hypertension or it can develop secondary to the heart failure itself, i.e. the cardiorenal syndrome. Unfortunately, limited progress has been made with respect to differentiation of these potential mechanistic subtypes of renal dysfunction. Currently in the field, we are relegated to using serum creatinine as one of the only diagnostic tools which has led to a poor understanding of cardiorenal syndrome and number of failed clinical trials for its treatment. This lecture will cover proposed mechanisms behind cardiorenal dysfunction in heart failure while addressing both flawed metrics in its diagnosis and treatment while also suggesting potential strategies moving forward by focusing on some challenging patient cases.

Objectives:
  • To understand that renal dysfunction in heart failure is mechanistically, prognostically and therapeuetically hetergeneous.
  • Learners will appreciate that low cardiac output is not the primary driver of renal dysfunction in heart failure.
  • To appreciate that all increases in creatinine are not detrimental or associated with increased mortality.
Friday
10:50am - 11:50am EDT - November 6, 2020
Jonathan Rich, MD, FACC
Credits Available:
1.00 CE

There has been a recent resurgence in the importance of the diabetes and cardiovascular disease interface. Specifically, new therapies have emerged that have been shown to improve cardiovascular outcomes considerably. Among these therapies are the class of agents called SLGT2 inhibitors. In addition to reducing CV risk in general, there is particular excitement about their potential in the management of patients with heart failure. However, there remains a generally low level understanding of not only how these drugs work but also how the should be prescribed and integrated into clinical practice. This session will address these topics.

Objectives:
  • Understand how SLGT2 inhibitors work.
  • Be aware of the data behind SLGT2 inhibitors in CV disease and the guidelines.
  • Consider incorporating SLGT2 inhibition into clinical practice including how to best collaborate with primary care and endocrinology.
Friday
This program is designed to educate on the current rates of heart failure in the US and identify the barriers to receiving advanced therapies. The program will highlight the work of a large US Heart Failure center and show how they have found success in getting more patients identified for treatment. The audience will benefit from hearing how they can grow their own heart failure programs and how Abbott products can help.
Friday
02:00pm - 03:00pm EDT - November 6, 2020
Dr. Samer Najjar, MD
Credits Available:
1.00 CE

Objectives:
  • Identify the major structures (chambers and valves) in ultrasound images of the heart.
  • Recognize and describe the standard views of transthoracic cardiac ultrasound and identify the utility of each view.
  • Review the role of echocardiography in the diagnosis and management of heart failure patients (systolic and diastolic dysfunction).
  • Discuss clinical situations that outline the use of this diagnostic study.
  • Review the most recent ACCF/AHA & HFSA Heart Failure Guidelines for the use of echocardiography in heart failure patients
Friday
03:30pm - 04:00pm EDT - November 6, 2020
Maureen Flattery, ANP-BC, CCTC
Credits Available:
0.50 CE

This session will review the changes made in the allocation of hearts form transplant that was adopted in October 2018. Maureen will include statistics as provided by UNOS and report on changes in practice that have occurred as a result of the changes in allocation.

Objectives:
  • Review the history of heart allocation.
  • Describe the new allocation system.
  • Discuss changes the new system has created in patient care.
Friday
04:00pm - 05:00pm EDT - November 6, 2020
Farooq Sheikh, MD
Credits Available:
1.00 CE

Objectives:
  • The audience will be able understand the mechanism of myocarditis and sarcoid cardiomyopathy. Diagnosis patterns for the inflammatory cardiomyopathies. Treatment for Myocarditis and Sarcoid.
Friday
This lecture will discuss the mechanism of CCM® Therapy and the clinical evidence behind this recently FDA approved technology for NYHA Class III HF patients. The faculty will discuss the therapy benefits and emphasize the importance of patient screening and NYHA Classification for patients being treated for Heart Failure. Optimizer® is designed to improve overall heart function and quality of life for patients living with heart failure. The faculty will share their experiences and what they have learned about CCM® therapy and give case-based examples of how you can determine patients that may be eligible for this device treatment option.

Objectives:
  • Review the indications for CCM® therapy.
  • Discuss the clinical studies and evidence supporting CCM® therapy.
  • Review the functionality of CCM® and patient benefits.
  • Outline regional vs. global effects of CCM® therapy.
Saturday


Objectives:
  • Define amyloidosis, including specific types and their cardiac features.
  • Identify barriers to patient identification and diagnosis.
  • Patient assessment criteria to differentially diagnose amyloidosis
  • Propose mechanisms to increase awareness of amyloidosis amongst heart failure providers and referring physicians.
  • Review current treatment options available for patients with amyloidosis.